UNLABELLED: The 'vanishing bone' syndrome multicentric osteolysis with nodulosis and arthropathy (MONA) is a rare chronic skeleton disorder caused by matrix metalloproteinase 2 (MMP2) deficiency, mimicking erosive polyarticular juvenile idiopathic arthritis. MONA is characterised by facial dysmorphism, subcutaneous fibrocollagenous nodules, carpal and tarsal osteolysis and interphalangeal joint erosions. We present the case of a 5-year-old boy with double outlet right ventricle, ventricular septal defect, coarctation of the aorta and MONA. Previously, a total of 24 cases of MONA have been reported of which six also had congenital cardiac malformations. Despite treatment attempts of our patient with methotrexate, eternacept and prednisolone, serial X-ray studies documented continuous severe bone degeneration. CONCLUSION: The case documents the natural history of MONA and establishes a link between MMP2 deficiency and heart development, and given the recurring cardiac association, we suggest that all MONA patients be examined for possible cardiac defects.
UNLABELLED: The 'vanishing bone' syndrome multicentric osteolysis with nodulosis and arthropathy (MONA) is a rare chronic skeleton disorder caused by matrix metalloproteinase 2 (MMP2) deficiency, mimicking erosive polyarticular juvenile idiopathic arthritis. MONA is characterised by facial dysmorphism, subcutaneous fibrocollagenous nodules, carpal and tarsal osteolysis and interphalangeal joint erosions. We present the case of a 5-year-old boy with double outlet right ventricle, ventricular septal defect, coarctation of the aorta and MONA. Previously, a total of 24 cases of MONA have been reported of which six also had congenital cardiac malformations. Despite treatment attempts of our patient with methotrexate, eternacept and prednisolone, serial X-ray studies documented continuous severe bone degeneration. CONCLUSION: The case documents the natural history of MONA and establishes a link between MMP2deficiency and heart development, and given the recurring cardiac association, we suggest that all MONA patients be examined for possible cardiac defects.
Authors: J A Martignetti; A A Aqeel; W A Sewairi; C E Boumah; M Kambouris; S A Mayouf; K V Sheth; W A Eid; O Dowling; J Harris; M J Glucksman; S Bahabri; B F Meyer; R J Desnick Journal: Nat Genet Date: 2001-07 Impact factor: 38.330
Authors: Rebecca A Mosig; Oonagh Dowling; Analisa DiFeo; Maria Celeste M Ramirez; Ian C Parker; Etsuko Abe; Janane Diouri; Aida Al Aqeel; James D Wylie; Samantha A Oblander; Joseph Madri; Paolo Bianco; Suneel S Apte; Mone Zaidi; Stephen B Doty; Robert J Majeska; Mitchell B Schaffler; John A Martignetti Journal: Hum Mol Genet Date: 2007-03-30 Impact factor: 6.150
Authors: Alberto Domínguez-Rodríguez; Juan C Kaski; Pedro Abreu-González; Martín J García-González Journal: Rev Esp Cardiol Date: 2008-03 Impact factor: 4.753
Authors: S A Temtamy; S Ismail; M S Aglan; A M Ashour; L A Hosny; T H El-Badry; E H A Aboul-Ezz; K Amr; E Fateen; T Maguire; K Ungerer; A Zankl Journal: Genet Couns Date: 2012
Authors: Andreas Zankl; Lauren Pachman; Andrew Poznanski; Luisa Bonafé; Fengqiang Wang; Yelena Shusterman; David A Fishman; Andrea Superti-Furga Journal: J Bone Miner Res Date: 2007-02 Impact factor: 6.741
Authors: C Rouzier; R Vanatka; S Bannwarth; N Philip; A Coussement; V Paquis-Flucklinger; J-C Lambert Journal: Clin Genet Date: 2006-03 Impact factor: 4.438
Authors: Matthew L Warman; Valerie Cormier-Daire; Christine Hall; Deborah Krakow; Ralph Lachman; Martine LeMerrer; Geert Mortier; Stefan Mundlos; Gen Nishimura; David L Rimoin; Stephen Robertson; Ravi Savarirayan; David Sillence; Juergen Spranger; Sheila Unger; Bernhard Zabel; Andrea Superti-Furga Journal: Am J Med Genet A Date: 2011-03-15 Impact factor: 2.802
Authors: Liisa Kröger; Tuija Löppönen; Leena Ala-Kokko; Heikki Kröger; Hanna-Mari Jauhonen; Kaisa Lehti; Jarmo Jääskeläinen Journal: Mol Genet Genomic Med Date: 2019-07-03 Impact factor: 2.183